Investor mix
5 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 40% |
| Other / undisclosed | 3 | 60% |
Developer of autologous cell therapies to enhance immune response for infectious diseases
5 investors on record.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 40% |
| Other / undisclosed | 3 | 60% |